» Articles » PMID: 37598213

Evidence of Leaky Protection Following COVID-19 Vaccination and SARS-CoV-2 Infection in an Incarcerated Population

Abstract

Whether SARS-CoV-2 infection and COVID-19 vaccines confer exposure-dependent ("leaky") protection against infection remains unknown. We examined the effect of prior infection, vaccination, and hybrid immunity on infection risk among residents of Connecticut correctional facilities during periods of predominant Omicron and Delta transmission. Residents with cell, cellblock, and no documented exposure to SARS-CoV-2 infected residents were matched by facility and date. During the Omicron period, prior infection, vaccination, and hybrid immunity reduced the infection risk of residents without a documented exposure (HR: 0.36 [0.25-0.54]; 0.57 [0.42-0.78]; 0.24 [0.15-0.39]; respectively) and with cellblock exposures (0.61 [0.49-0.75]; 0.69 [0.58-0.83]; 0.41 [0.31-0.55]; respectively) but not with cell exposures (0.89 [0.58-1.35]; 0.96 [0.64-1.46]; 0.80 [0.46-1.39]; respectively). Associations were similar during the Delta period and when analyses were restricted to tested residents. Although associations may not have been thoroughly adjusted due to dataset limitations, the findings suggest that prior infection and vaccination may be leaky, highlighting the potential benefits of pairing vaccination with non-pharmaceutical interventions in crowded settings.

Citing Articles

Vaccine failure mode determines population-level impact of vaccination campaigns during epidemics.

Lee D, Nande A, Anderson T, Levy M, Hill A J R Soc Interface. 2025; 22(223):20240689.

PMID: 39965640 PMC: 11835492. DOI: 10.1098/rsif.2024.0689.


Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19.

Nakayama E, Shioda T Pathogens. 2025; 13(12.

PMID: 39770368 PMC: 11728538. DOI: 10.3390/pathogens13121109.


Protection from prior natural infection vs. vaccination against SARS-CoV-2-a statistical note to avoid biased interpretation.

Weber S, Hedberg P, Naucler P, Wolkewitz M Front Med (Lausanne). 2024; 11:1376275.

PMID: 38933111 PMC: 11199770. DOI: 10.3389/fmed.2024.1376275.


Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China.

Guo Z, Zeng T, Lu Y, Sun S, Liang X, Ran J Commun Med (Lond). 2024; 4(1):92.

PMID: 38762678 PMC: 11102477. DOI: 10.1038/s43856-024-00521-y.


The Risk of SARS-CoV-2 Transmission in Community Indoor Settings: A Systematic Review and Meta-analysis.

Francis M, Gidado S, Nuorti J J Infect Dis. 2024; 230(4):e824-e836.

PMID: 38753340 PMC: 11481457. DOI: 10.1093/infdis/jiae261.


References
1.
Tillett R, Sevinsky J, Hartley P, Kerwin H, Crawford N, Gorzalski A . Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020; 21(1):52-58. PMC: 7550103. DOI: 10.1016/S1473-3099(20)30764-7. View

2.
Chen J, Wang R, Gilby N, Wei G . Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model. 2022; 62(2):412-422. PMC: 8751645. DOI: 10.1021/acs.jcim.1c01451. View

3.
Bowen J, Addetia A, Dang H, Stewart C, Brown J, Sharkey W . Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science. 2022; 377(6608):890-894. PMC: 9348749. DOI: 10.1126/science.abq0203. View

4.
Lind M, Copin R, McCarthy S, Coppi A, Warner F, Ferguson D . Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. J Infect Dis. 2022; 227(5):663-674. DOI: 10.1093/infdis/jiac453. View

5.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View